Upgrade to SI Premium - Free Trial

Amgen (AMGN) to Present Latest EVENITY (Romosozumab) And Prolia (Denosumab) Research

September 8, 2017 9:04 AM
Amgen (NASDAQ: AMGN) today announced that 19 scientific abstracts will highlight the latest scientific research on EVENITY™* (romosozumab) and ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Hot Corp. News

Next Articles